Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.
GLP-1 receptor agonist use associated with higher rate of upper eyelid blepharoplasty
Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have transformed the management of obesity and type 2 diabetes.
This study evaluates whether GLP-1 RA therapy is associated with an increased rate of upper eyelid blepharoplasty.
Prescribed GLP-1 RA comprised the exposure cohort; patients without GLP-1 RA served as controls.
GLP-1 users had eyelid-lift surgery far more often than non-users
A total of 821,792 eligible female patients were identified, of whom 28,970 received GLP-1 RA therapy.
After propensity score matching, 23,349 patients remained in each cohort.
At five-year follow-up, 96 GLP-1 RA users (0.41%) underwent blepharoplasty compared with 36 controls (0.15%).
In the secondary analysis, non-GLP-1 RA weight loss was not associated with increased blepharoplasty incidence (hazard ratio 1.31; 95% confidence interval 0.89-1.93; p = 0.56).
GLP-1 receptor agonist use is associated with a significantly increased rate and earlier timing of upper eyelid blepharoplasty compared with matched controls.
Weight loss alone did not demonstrate the same association, suggesting a distinct pattern of facial remodeling related to GLP-1 RA therapy.
As pharmacologic weight loss expands, plastic surgeons should anticipate increased demand for periorbital rejuvenation and counsel patients accordingly.